Agios
Agios Pharmaceuticals, often referred to simply as Agios, is a prominent biopharmaceutical company headquartered in the United States. Founded in 2008, Agios has established itself as a leader in the field of metabolic oncology, focusing on the discovery and development of innovative therapies for cancer and rare genetic diseases. With a strong emphasis on precision medicine, Agios has made significant strides in developing unique small molecule drugs that target specific metabolic pathways. Their flagship products, including therapies for acute myeloid leukaemia and hereditary cancer syndromes, highlight the company's commitment to addressing unmet medical needs. Recognised for its pioneering research and development efforts, Agios continues to solidify its market position through strategic partnerships and a robust pipeline of potential treatments, making it a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Agios's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Agios's score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Agios's reported carbon emissions
Agios Pharmaceuticals, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges outlined in their sustainability initiatives. As of now, Agios has not cascaded any emissions data from a parent or related organization, meaning their climate commitments and performance metrics are independently reported. Without specific emissions data or reduction targets, it is unclear how Agios is addressing its carbon footprint or contributing to broader climate goals within the pharmaceutical industry. In the absence of concrete figures or commitments, it is essential for Agios to establish clear climate strategies and targets to align with industry standards and expectations for sustainability.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Agios is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
